Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials

BACKGROUND: High sustained virological response at 12 weeks after end of treatment (SVR12) with 12 weeks of simeprevir and sofosbuvir±ribavirin (SMV+SOF±RBV) has been demonstrated in hepatitis C virus genotype 1 (HCV-1) but is based on limited data. Therefore, we performed a meta-analysis of availab...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMJ Open Gastroenterol
Asıl Yazarlar: Yee, Brittany E, Nguyen, Nghia H, Jin, Minjuan, Lutchman, Glen, Lim, Joseph K, Nguyen, Mindie H
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2016
Konular:
Meta Analysis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4780041/
https://ncbi.nlm.nih.gov/pubmed/26966547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2015-000056
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller